A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate [alendronic acid] in Postmenopausal Women With Low Bone Mineral Density.

Trial Profile

A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate [alendronic acid] in Postmenopausal Women With Low Bone Mineral Density.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DAPS
  • Sponsors Amgen
  • Most Recent Events

    • 01 Jan 2012 Final results published in Osteoporosis International.
    • 23 Mar 2011 Results have been presented at ECCEO11-IOF according to an Amgen media release; results were also reported in the media release.
    • 08 May 2010 Status changed from active, no longer recruiting to completed, according to results reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top